Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company that discovers and develops therapeutic products to treat and prevent serious infectious diseases and cancers. The company's clinical development pipeline is highlighted by its investigational therapies targeting chronic hepatitis delta (CHD) and novel masked T-cell engagers for solid tumors. Vir utilizes multiple technology platforms, including protein engineering, AI/ML optimization, and its exclusive PRO-XTEN masking technology. Its key clinical programs include the combination of tobevibart and elebsiran for HDV, as well as oncology candidates targeting HER2, PSMA, and EGFR. The company actively collaborates with major pharmaceutical partners and organizations, such as Astellas, Alnylam Pharmaceuticals, and the Bill & Melinda Gates Foundation, to advance its pipeline and maximize the value of its therapeutic candidates.
